The convergence of molecular diagnostics and artificial intelligence-driven digital pathology: A biotechnological approach to precision medicine
Background
Limitations of precision medicine and emerging needs
Traditional diagnostics primarily relied on microscopic observation of cellular or tissue morphology. This approach is prone to subjective interpretation by physicians and makes it difficult to assess intratumoral heterogeneity. In diseases such as cancer and autoimmune disorders, where the pathogenesis varies among patients, it is often challenging to provide appropriate treatment based solely on morphological analysis.
Biotechnology, which integrates molecular biology, nanotechnology, and computer science, has provided a foundation for overcoming these limitations. Molecular diagnostics, which analyzes gene mutations and biomarker expression patterns, and multi-omics technologies are representative examples. These technologies elucidate disease mechanisms at the genetic level and support the design of personalized treatments. To achieve high precision and minimize adverse effects, a mechanism-based diagnostic system is essential for targeted therapies.
Key Findings
High-dimensional data-driven diagnostics and targeted therapies
The advancement of biotechnology is transforming diagnostic and therapeutic strategies. Molecular diagnostics and multi-omics contribute to elucidating the pathogenesis of various diseases, including cancer, genetic disorders, infectious diseases, cardiovascular diseases, and autoimmune diseases. Researchers have established diagnostic protocols that integrate gene mutation information and biomarker expression patterns to evaluate cellular heterogeneity and immune regulatory mechanisms.
In the therapeutic field, gene editing, nanomedicine, immunotherapy, and targeted drug delivery are driving progress. Nanoparticle-based targeted delivery systems have significantly reduced the toxicity of drugs to normal tissues. Gene editing plays a role in correcting the underlying genetic cause of the disease, paving the way for mechanism-based precision therapy.
Introduction of artificial intelligence-driven digital pathology
The development of digital pathology analysis, which combines artificial intelligence (AI) and bioinformatics, is also noteworthy. Machine learning and deep learning are key technologies for capturing subtle pathological information through whole-slide image (WSI) analysis. Digital pathology systems integrate multi-dimensional data and clinical information to discover new biomarkers and classify patient risk. The combination of morphological and molecular data in pathology techniques is expected to become a new standard for distinguishing disease subtypes.
Significance and Prospects
Overcoming challenges for commercialization
Convergent biotechnology is a key driver in accelerating the implementation of precision medicine. The combination of genetic analysis and targeted therapy is expected to realize personalized medicine. Academia and industry anticipate that this approach can reduce diagnostic errors and improve treatment efficacy, particularly in high-cost cancer treatments and rare diseases.
However, there are several challenges to be addressed before clinical implementation. High costs of analytical equipment and technical complexity increase the financial burden on healthcare institutions. The lack of standardization of multi-omics and AI learning data hinders data sharing between institutions. Furthermore, consensus is needed on issues related to the exposure of personal genomic information and bioethical legal issues.
Technology democratization for reducing healthcare disparities
Therefore, future research should focus on technology democratization. The development of point-of-care (POC) molecular diagnostics and biosensor platforms that can be used in resource-limited healthcare settings is a major challenge. The commercialization of low-cost platforms is expected to enable patients in underserved areas to benefit from precision diagnostics, thereby reducing healthcare disparities.
Biotechnology in modern medicine and pathology encompasses molecular diagnostics, multi-omics analysis, nanotechnology-enabled platforms, digital pathology, bioinformatics, and computational approaches that support disease detection, therapeutic development, and clinical decision-making. This review examines how these technologies have contributed to diagnostic workflows, therapeutic development, disease classification, and clinical decision-making in contemporary healthcare. The integration of molecular biology, nanotechnology, and computational sciences has expanded the evaluation of disease-related processes such as genetic variation, biomarker expression, tumor heterogeneity, immune regulation, and molecular pathway alterations in conditions including cancer, inherited disorders, infectious diseases, cardiovascular disease, and autoimmune disease. Therapeutic innovations such as gene editing, nanomedicine, immunotherapy, biologics, and targeted drug delivery systems have further supported mechanism-based treatment strategies by improving tissue targeting, reducing off-target toxicity, and enabling more individualized therapeutic planning. Artificial intelligence (AI) and bioinformatics approaches, including machine learning, deep learning, computational pathology, digital whole-slide image analysis, and omics-data integration, have supported biomarker discovery, disease classification, diagnostic image analysis, risk stratification, and pathology-based clinical decision support. Additionally, molecular and digital pathology have improved disease subclassification and prognostic assessment by integrating histomorphologic findings with molecular and computational data. Despite these advances, high costs, technical complexity, data standardization challenges, infrastructure limitations, and ethical concerns continue to restrict widespread clinical adoption. Future work should prioritize low-cost point-of-care molecular and biosensor platforms for resource-limited settings.
This study demonstrates a roadmap for transforming precision diagnostics, which has traditionally relied on expensive equipment and complex laboratory tests, into a healthcare-integrated approach. A specific application scenario is the use of microfluidics-based biosensor chips in healthcare facilities, including large hospitals, health centers, and local clinics, to identify cancer gene mutations in a patient's single drop of blood within 30 minutes. In addition, portable digital scanners equipped with AI models can perform primary slide readings in remote areas or developing countries with limited access to pathologists, reducing the rate of misdiagnosis. From a pharmaceutical industry perspective, this approach can be immediately incorporated into commercialization strategies by pre-selecting clinical trial participants using multi-omics analysis, thereby maximizing the efficacy of new drug candidates and increasing the success rate of new drug development.